BSX · 10-Q · 2026Q2 · Full report

Geographic Market Commentary

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 31 · Surprise 32

China was a specific area of weakness in Boston Scientific’s Urology business during the second quarter and first six months of 2026. The company attributed underperformance in its stone franchise to volume-based procurement in China. This procurement environment contributed to Urology organic sales growth of only 0.6% for the first six months, materially below the company’s overall 8.1% organic growth.